Free Trial

Plus Therapeutics Q1 2024 Earnings Report

Plus Therapeutics logo
$1.16 -0.36 (-23.68%)
As of 03/28/2025 04:00 PM Eastern

Plus Therapeutics EPS Results

Actual EPS
-$0.75
Consensus EPS
-$1.09
Beat/Miss
Beat by +$0.34
One Year Ago EPS
-$2.10

Plus Therapeutics Revenue Results

Actual Revenue
$1.68 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Plus Therapeutics Announcement Details

Quarter
Q1 2024
Time
After Market Closes
Remove Ads

Plus Therapeutics Earnings Headlines

Trump’s Great Society
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Plus Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Plus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Plus Therapeutics and other key companies, straight to your email.

About Plus Therapeutics

Plus Therapeutics (NASDAQ:PSTV), a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

View Plus Therapeutics Profile

More Earnings Resources from MarketBeat